nach oben

International Journal of Colorectal Disease

Erschienen in:

01.03.2004 | Review

Gene therapy in the treatment of intestinal inflammation

verfasst von: Catherine van Montfrans, Anje A. te Velde, Sander J. H. van Deventer, Maria Sol Rodriguez Pena

Erschienen in: International Journal of Colorectal Disease | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Background

Local expression of anti-inflammatory or immunoregulatory genes may offer an alternative treatment of gastrointestinal inflammation.

Discussion

We review the basic requirements for gene therapy, the possible routes of delivery, and the different strategies for specific targeting focusing on gastrointestinal inflammation.

Pawel BR, de Chadarevian JP, Franco ME (1997) The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Hum Pathol 28:395–399PubMed

Cummings OW (2000) Pathology of the adenoma-carcinoma sequence: from aberrant crypt focus to invasive carcinoma. Semin Gastrointest Dis 11:229–237PubMed

Granger DN, Korthuis RJ (1995) Physiologic mechanisms of postischemic tissue injury. Annu Rev Phys 57:311–332CrossRef

MacNaughton WK (2000) Review article: new insights into the pathogenesis of radiation-induced intestinal dysfunction. Aliment Pharmacol Ther 14:523–528CrossRefPubMed

Jankowski JA (2000) Barret's metaplasia. Lancet 356:2079–2085CrossRefPubMed

Sollid LM (2000) Molecular basis of celiac disease. Annu Rev Immunol 18:53–81PubMed

Schuppan D (2000) Current concepts of celiac disease pathogenesis. Gastroenterology 119:234–242PubMed

Heneghan MA, Moran AP (2001) Helicobacter pyroli, Lewis antigens, and inflammation. Gut 48:869CrossRef

Anderson WF (1998) Human gene therapy. Nature 392:25–30CrossRef

10.

Hedley ML (2000) Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 44:195–207CrossRefPubMed

11.

Young LS, Mautner V (2001) The promise and potential hazards of adenovirus gene therapy. Gut 48:733–736CrossRefPubMed

12.

Rennick DM, Fort MM (2000) Lessons from genetically engineered animal models-XII. IL-10-deficient (IL-10 (–/–)) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physioly 278:G829–G833

13.

Deventer SJH van, Elson CO, Fedorak RN, Group CsDS (1997) Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 113:383–389

14.

Montfrans C van, et al (2002) Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 50:191–195CrossRefPubMed

15.

Miller DG, Adam MA, Miller AD (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239–4342

16.

Halene S, Kohn DB (2000) Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther 11:1259–1267CrossRefPubMed

17.

Bukrinsky MI, Haffar OK (1999) HIV-1 nuclear import: in search of a leader. Front Biosci 4:D772–D781PubMed

18.

Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173–185PubMed

19.

Russell WC (2000) Update an adenovirus and its vectors. J Gen Virol 81:2573–2604PubMed

20.

Walther W, Stein U (2000) Viral vectors for gene transfer—a review of their use in the treatment of human diseases. Drugs 60:249–271PubMed

21.

Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7:33–40

22.

Marshall E (2002) Clinical research: gene therapy a suspect in leukemia-like disease. Science 298:34–35CrossRefPubMed

23.

Powell SK, Kaloss M, Burimski I, Weaver L, Long Z, Lyons R, McGarrity GJ, Otto E (1999) In vitro analysis of transformation potential associated with retroviral vector insertions. Hum Gene Ther 10:2123–2132CrossRefPubMed

24.

Amado RG, Chen IS (1999) Lentiviral vectors-the promise of gene therapy within reach? Science 285:674–676

25.

Federico M (1999) Lentiviruses as gene delivery vectors. Curr Opin Biotechnol 10:448–453CrossRefPubMed

26.

Verma IM, Somia N (1997) Gene therapy—promises, problems and prospects. Nature 389:239–242

27.

Reiser J (2000) Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 7:910–913CrossRefPubMed

28.

Vigna E, Naldini L (2000) Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2:308–316CrossRefPubMed

29.

Trono D (2000) Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 7:20–23CrossRefPubMed

30.

Seppen J, Barry SC, Klinkspoor JH, Katen LJ, Lee SP, Garcia JV, Osborne WR (2000) Apical gene transfer into quiescent human and canine polarized intestinal epithelial cells by lentivirus vectors. J Virol 74:7642–7645CrossRefPubMed

31.

Cheng DY, Kolls JK, Lei D, Noel RA (1997) In vivo and in vitro gene transfer and expression in rat intestinal epithelial cells by E1-deleted adenoviral vector. Hum Gene Ther 8:755–764PubMed

32.

Lindsay JO, Ciesielski CJ, Feldmann M, Brennan FM (2000) The stable infection of epithelial cell lines and primary rabbit colon cells with an adenovirus encoding murine interleukin-10 (mIL-10) generates bioactive cytokine at therapeutic concentrations. Gastroenterology a 3035

33.

Lindsay J, van Montfrans C, Brennan F, van Deventer S, Drillenburg P, Hodgson H, te Velde A, MS RP (2002) IL-10 gene therapy prevents TNBS induced colitis. Gene Ther 9:1715–1721CrossRefPubMed

34.

Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W (2000) Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med 192:41–52CrossRefPubMed

35.

During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P (1998) Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 4:1131–1135CrossRefPubMed

36.

Lindsay JO, Cathleen J, Ciesielski FMB, Humphrey J, Hodgson (2001) Rectal administration of an adenoviral vector encoding IL-10 induces colonic IL-10 release with minimal anti-adenoviral response. Gastroenterology a 3715

37.

Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P (2000) Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther 11:1731–1741CrossRefPubMed

38.

Ayuk FA, Li Z, Kuhlcke K, Lindemann C, Schade UM, Eckert HG, Zander AR, Fehse B (1999) Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther 6:1788–1792CrossRefPubMed

39.

Movassagh M, Boyer O, Burland M, Leclercq L, Klatzmann D, and Lemoine FM (2000) Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum Gene Ther 11:1189–1200CrossRefPubMed

40.

Dardalhon V, Jaleco S, Rebouissou C, Ferrand C, Skander N, Swainson L, Tiberghirn P, Spits H, Noraz N, Taylor N (2000) Highly efficient gene tranfer in naive human T cells with a murine leukemia virus-based vector. Blood 96:885–893PubMed

41.

Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:475–480PubMed

42.

Anderson WF (2000) Gene therapy. The best of times, the worst of times. Science 288:627–629CrossRefPubMed

43.

Cavazzano-Calvo M, Hacein-Bey S, de Saint Basile G, Gross G, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Le Deist F, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672CrossRefPubMed

44.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719–1724CrossRefPubMed

45.

Chen LZ, Hochwald GM, Huang C, Dakin G, Tao H, Cheng C, Simmons WJ, Dranoff G, Thorbecke GJ (1998) Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc Natl Acad Sci U S A 95:12516–12521CrossRefPubMed

46.

Setoguchi K, Misaki Y, Araki Y, Fujio K, Kawahata K, Kitamura T, Yamamoto K (2000) Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J Immunol 165:5980–5986PubMed

47.

van Montfrans C, Hooijberg E, Rodriguez-Pena M, de Jong E, Spits H, te Velde A, van Deventer S (2002) Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer. Gastroenterology 123:1877–1888CrossRefPubMed

48.

Montfrans C van, Rodriguez-Pena M, Pronk I, ten Kate F, te Velde A, van Deventer S (2002) Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology 123:1865–1876CrossRefPubMed

49.

Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507–529PubMed

50.

Bonini C, Lee SP, Riddell SR, Greenberg PD (2001) Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 166:5250–5257PubMed

51.

Legge KL, Gregg RK, Maldonado-Lopez R, Li L, Caprio JC, Moser M, Zaghouani H (2002) On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med 196:217–227CrossRefPubMed

52.

Lipscomb MF, Masten BJ (2002) Dendritic cells: immune regulators in health and disease. Physiol Rev 82:97–130PubMed

53.

Feili-Hariri M, Dong X, Alber S, Watkins S, Salter R, Morel P (1999) Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 48:2300–2308PubMed

54.

Khoury S, Gallon L, Chen W, Betres K, Russell M, Hancock W, Carpenter C, Sayegh M, Weiner H (1995) Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med 182:357–366PubMed

55.

Vile RG, Sunassee K, Diaz RM (1998) Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today 4: 84–92PubMed

56.

Peng KW (1999) Strategies for targeting therapeutic gene delivery. Mol Med Today 5:448–453CrossRefPubMed

57.

Peng KW, Russell SJ (1999) Viral vector targeting. Curr Opin Biotechnol 10:454–457CrossRefPubMed

58.

Sweetser DA, Birkenmeier EH, Hoppe PC, McKeel DW, Gordon JI (1988) Mechanisms underlying generation of gradients in gene expression within the intestine: an analysis using transgenic mice containing fatty acid binding protein-human growth hormone fusion genes. Genes Dev 2:1318–1332PubMed

59.

Marin M, Noel D, Piechaczyk M (1997) Towards efficient cell targeting by recombinant retroviruses. Mol Med Today 3:396–403CrossRefPubMed

60.

Sommerfelt M (1999) Retrovirus receptors. J Gen Virol 80:3049–3064PubMed

61.

Gallardo H, Tan C, Ory D, Sadelain M (1997) Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90:952–957PubMed

62.

Lodge R, Subbramanian RA, Forget J, Lemay G, Cohen EA (1998) MuLV-based vectors pseudotyped with truncated HIV glycoproteins mediate specific gene transfer in CD4+ peripheral blood lymphocytes. Gene Ther 5:655–664CrossRefPubMed

63.

Hanauer SB, Dassopoulos T (2001) Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med 52:299–318CrossRefPubMed

64.

Ghosh S, May MJ, Kopp EB (1998) NFkB and rel proteins: evolutionarily conserved mediators of immune response. Annu Rev Immunol 16:225–260PubMed

65.

Makarov SS (2000) NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 6:441–448PubMed

66.

Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7–11PubMed

67.

Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17:701–738CrossRefPubMed

68.

Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765

69.

Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27–55PubMed

70.

Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331–367

71.

Hasko G, Szabo C (1999) IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. Br J Pharmacol 127:1295–1304PubMed

72.

Coyle AJ, Gutierrez-Ramos JC (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2:203–209CrossRefPubMed

73.

Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ (1996) Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 14:591–617PubMed

74.

Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2000) The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 1:469–474CrossRefPubMed

Titel: Gene therapy in the treatment of intestinal inflammation
verfasst von: Catherine van Montfrans
Anje A. te Velde
Sander J. H. van Deventer
Maria Sol Rodriguez Pena
Publikationsdatum: 01.03.2004
Verlag: Springer-Verlag
Erschienen in: International Journal of Colorectal Disease / Ausgabe 2/2004
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-003-0501-4

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2004

Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study

A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene

Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization

Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy

Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression

Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue

Update Chirurgie